Anbio Biotechnology Class A Ordinary Shares
Anbio Biotechnology Class A Ordinary Shares (NNNN) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · NNNN · as of Sep 30, 2025
Ownership Breakdown
10
Institutional Holders
▲ 5 vs Q2
$2.54M
Total Inst. Value
▲ $1.61M vs Q2
43.89M
Shares Outstanding
freeFloat 90.43%
68,305
13F Shares Held
▲ 38,719 vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
NNNN largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
GEODE CAPITAL MANAGEMENT, LLC in vitro & in vivo diagnostic substances | 25.8K | 5.87% | 5.87% | $959.67M | Nov 12, 2025 | ▲ 8.6K |
MARSHALL WACE, LLP in vitro & in vivo diagnostic substances | 10.4K | 2.38% | 2.38% | $389.00M | Nov 13, 2025 | ▲ 10.4K |
MORGAN STANLEY in vitro & in vivo diagnostic substances | 8.6K | 1.96% | 1.96% | $320.72M | May 27, 2026 | ▲ 8.2K |
MILLENNIUM MANAGEMENT LLC in vitro & in vivo diagnostic substances | 7.1K | 1.61% | 1.61% | $263.73M | Nov 14, 2025 | NEW |
XTX TOPCO LTD in vitro & in vivo diagnostic substances | 6.9K | 1.57% | 1.57% | $256.88M | Nov 14, 2025 | NEW |
HRT FINANCIAL LP in vitro & in vivo diagnostic substances | 6.0K | 1.37% | 1.37% | $223.00M | Nov 14, 2025 | NEW |
BNP PARIBAS ARBITRAGE, SNC in vitro & in vivo diagnostic substances | 2.4K | 0.55% | 0.55% | $90.11M | Nov 13, 2025 | ▲ 1.2K |
UBS GROUP AG in vitro & in vivo diagnostic substances | 960 | 0.22% | 0.22% | $35.76M | Nov 13, 2025 | ▼ 9.7K |
WELLS FARGO & COMPANY/MN in vitro & in vivo diagnostic substances | 100 | 0.02% | 0.02% | $3.73M | Nov 13, 2025 | — held |
BANK OF AMERICA CORP /DE/ in vitro & in vivo diagnostic substances | 21 | 0.00% | 0.00% | $782,000 | Feb 3, 2026 | NEW |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
4
Increased
+28.4K shares4
New Positions
first time holders1
Decreased
−9.7K shares0
Sold Out
fully exitedNet shares change (top 50)
+18.7K
+28.4K / −9.7K
Net new holders
+7
4 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
NNNN insider trading · insider activity
Source: SEC Form 4
Recent Insider Transactions
Showing 10 most recent · Common Stock only
No recent insider transactions reported.
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Anbio Biotechnology Class A Ordinary Shares (NNNN) is primarily owned by institutional investors, who hold approximately 0.2% of total shares outstanding. Company insiders own approximately 9.57%, while retail and public investors account for the remaining 90.28%.
The largest institutional shareholder of Anbio Biotechnology Class A Ordinary Shares is GEODE CAPITAL MANAGEMENT, LLC, holding approximately 25,763 shares — equal to 5.87% of outstanding shares — as of September 30, 2025.
A total of 10 institutional investors currently hold NNNN stock, with a combined institutional value of approximately $2,543,378 as of the most recent 13F filing period.
Frequently asked questions
NNNN ownershipAnbio Biotechnology Class A Ordinary Shares (NNNN) is primarily owned by institutional investors, who hold approximately 0.2% of shares. The largest shareholder is GEODE CAPITAL MANAGEMENT, LLC with a 5.87% stake. Company insiders hold 9.57%. Data sourced from SEC Form 13F as of September 30, 2025.